summarize deeper our pipeline to Thank start you, by plans trial our into clinical will eager bit and CLS-AX programs. then George. a I I'm diving other
to IND the we open we year. announce initiate Wet I/IIa studies CLS-AX As today clinical With FDA. our to by now with and George that by AMD mentioned patients of were our able the into the phase accepted progress this human in pleased trial IND was end are
suprachoroidal asset can its that intrinsic to for We excited leveraged advance further characteristics this delivery. are be through
designed have than TKIs. a as inhibited kinase and axitinib is Tyrosine more TKI independent First achieve inhibitor potently other that or to either showed or anti-VEGF neovascularization inhibition axitinib focused studies pre-clinical pan-VEGF inhibition
AMD. versus fluorescein concentration in vessel reduction choroid CLS-AX leakage controls concentration to Second, of vitreous lower the suprachoroidal and administered demonstrated models new leading in of retina in with hydride growth Wet targeted the effective and
the dose. models need. demonstrated compartmentalization animal trials starting some tolerated the Wet suprachoroidal human burden CLS-AX at first It anterior the systemic models. look well large in when our of signs This was to animal forward AMD, CLS-AX toxicity showed intended sparing clinical a circulation. potential eye durability benefits in treatment chamber no unmet current supports the and administered CLS-AX. suprachoroidal and Third, administered with to of the multi-month finally clinical address We in And with
AMD an label following CLS-AX We to safety be with Eligible administered and individual of phase a of through are study in dose those acuity injections demonstrate assess single patients are I/IIa agent. planning or Wet two escalation to stable patients tolerability visual anti-VEGF dose injection. the trial more our an suprachoroidal who clinical open previous
trial these we flipper primary our For tolerability be AMD plan the will Wet the use safety and The as CLS-AX trial a for set to of patients. anti-VEGF this in endpoints agent. to assess
is targeted pharmacokinetics, a evaluate total a whether photoseptic of intravitreal followed the suprachoroidal study Secondary additional Patients ocular The given. anatomy patients month a followed of with Eligible the to for for cohorts patients therapy include will assessments visit study of individual set. baseline flipper the XX need the receive design will a of treatment for on function, treatment approximately be each additional additional injection potential two three visits anatomy milligram with later. population tolerability, endpoints of patients. five injection ocular flipper for visual and visual safety, through set. by three returned will All fifth for and regardless a function, the CLS-AX one is at further need screening patients
study in following review of safety recommendation design will calls of the suprachoroidal higher one escalation monitoring escalation three the dose For then X.XX data the to by delivered Cohort CLS-AX the next proceed of advance each cohorts. lowest dose by the the will Dose milligrams start safety injection. dose for at and of committee axitinib cohort.
approximately each months. With at the cohort for timeline six
We from expect first the safety in cohort data mid-XXXX. initial
our Internally are potential Wet advance teams that discovery a trial CLS-AX this goal. for reach and is AMD step long-acting to our about excited to research first phase We pre-clinical as programs. the therapy continue for I/IIa our and
is development pre-clinical vectors We well-established genes in like nanoparticles for and common nanoparticle viral have biofactory pre-clinical disease. large a too nanoparticle for of AAV. There DNA literature retinal internal supporting program models that sub-retinal DNA transfer can therapy are DNA pipeline. gene gene
nanoparticles biofactory administration approach. leakage experimental based less approach at suprachoroidal In anti-VEGF RAT the of addition, expression and the non-viral at vascular Johns they capsid vectors. With antigens nanoparticles yield a repeat undergo office nanoparticles RTE In demonstrated and throughout It to showed gene. of successful an containing neovascularization a published than viral can via with paper that model. protein could for photoreceptors reporter DNA in Hopkins they since of suprachoroidal suprachoroidal of VEGF are a recently induced this were immunogenic potentially and lack eight months. viral gene pre-clinical suppress researchers injection also able least corresponding non-viral eye expression their therapeutic They have dosing
marker of compared yields gene We have nanoparticles similar administration suprachoroidal activity that administration. subretinal shown previously to DNA
with been transgenes therapeutic Over the pre-clinical nanoparticles we've in model. working year a containing last DNA
than clinically We suprachoroidal model. this better have in that observed administration animal tolerated is intravitral administration
we Suprachoroidal peripheral We opening have for most the suprachoroidal seen way suprachoroidal retinal DNA have is three thoroughly potential potential disorders. address without all subretinal the as the therapy nanoparticle DNA these of the Furthermore, posteriorly studies gene also And and based there protein by targets the address in importantly gene of transgene administration supporting disorders. months repeatable results. nerve the more duration macular of surgery process for and space and imaged an are the the administration as to has quantitating to both demonstrated the vitrectomy Johns out expression the teams, after preliminary potential of therapy to different nanoparticles of the optic swap signs administration. to of and office Hopkins risk
We injector and approach. native about for using are of gene platform the our potential micro excited replacement both biofactory this a SCS
Next program targeting to disease. discuss want I pathway retinal a pre-clinical important in another potential
as Most molecules adhesion represent aptosis. such regulate pre-clinical studies an novel in We our had migration, target integrant a a angiogenesis competition. survival macular invasion, with Integrins fibrosis. has cell maculoedema of have added in recently role critical and diabetic to play of inflammation, program. development processes clinical and adhesion, pre-clinical processes cell Integrins limited in some Integrins importantly proliferation, pathologic inhibitor that multi-functional validation inhibition they and as and recent early such models degeneration. early
therapy Integrins action inhibitor delivery with just over may small and exceptional durability macular therapy, of could degeneration. acetonide Suprachoroidal targeted, serve inter-vitro primary therapy pre-clinically. have secondary integrins in agents adjunctive and/ mechanism clinically refractory triamcinolone cases or suspensions or potentially and anti-VEGF inhibition of advantages delivery suspension diabetic macular to unique their of topical Given an as molecule of and edema as compartmentalization we seen provide
to additional processes in of potential macular inhibitor pathologic integrin address diabetic planning suspension. studies macular we're with the a pre-clinical generation and the series our edema Given
Next I our touch would briefly plans on like to from the partners. development
the oncology of a Biosciences. Aura June We suprachoroidal Aura asset drug of and use AU-XXX licensing SCS the to micro-injector the into distribution our cancers. space are for certain research proprietary of third to completed pre-clinical agreement very Aura our has efficacy candidates treatment the laser of distribution Aura of a delivered to its data of the their rabbit clinical very ocular Aura At AU-XXX presented via progress potential deliver for a pleased of According with suprachoroidal SCS phase tumors melanoma. of expects delivery partner a in regarding the ocular necrosis the [Aura] Preclinical Microinjector. and following in during of show initiate chordal activation model studies XXXX. our been trial suprachoroidal and space in quarter X impressive AU-XXX the have worldwide evaluating
non-surgical Our deliver cohort their patient patients treatment. enroll this AAV AAV the evaluate of end their Wet Microinjector XXXX. are dosing this and quarter phase delivery XX entitled of of trial first report will that last severe patients REGENXBIO interim begin suprachoroidal expect treatment. to our partner AAV by X is utilizing their announced data the Wet week with gene in will patients therapy with SCS with one-time of and proprietary is AMD RGX-XXX AMD. populations who from to different anti-VEGF to access is plan responsive offering to to RGX-XXX two trial They trial active to gene hope the in-office They two
phase also In initiate delivery using addition and to second suprachoroidal diabetic half expects to Wet retinopathy of X in XXXX. for trial REGENXBIO the AMD a RGX-XXX
therapy the Retina early ophthalmology XIPERE. these programs at Importantly Specialists. and meetings the research our with and our over presented XX ophthalmic publications pandemic data several current retina we mind virtual retina for the delivery specialists of and to platform, posters events the and At and stay association top for suprachoroidal continue despite and axitinib and on vision communities the American with presented environment Society of gene annual
development retina their now to to expertise treatment recently target pipeline clinicians our input Charlie I call for approach needs turn tap we world-renowned to physicians could from receive continue into results. this scientific over and as five our our review will to financial advisory To leverage positive comprised a how patients. advance plans. the we unmet formed CFO, their our suprachoroidal We feedback board of Deignan
